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Introduction
This month, we discuss three papers which publish the
results of trials into potential treatment approaches to
myasthenia gravis (MG). When treatment with cholines-
terase inhibitors alone fails to control symptoms, treatment
with steroids may be required, often at high doses which
are often associated with adverse side effects both in the
short and long term. All the studies explore treatments that
may replace or reduce the need for steroids in MG and use
the quantitative myasthenia gravis (QMG) score and
prednisone dose requirement as primary or secondary
outcomes. The first paper reports results of a randomised
trial of routine thymectomy in non-thymomatous MG
patients, the results of which may see this procedure
incorporated into routine management of non-thymoma-
tous MG. The second and third papers explore alterna-
tive steroid-sparing immunosuppressive agents. At present,
the only medications shown to be effective in randomised
placebo-controlled studies are azathioprine and cyclospor-
ine, but both carry the risk of adverse reactions and have a
requirement for close monitoring. The second study com-
pares methotrexate and prednisone treatment to prednisone
alone and the final study assesses effectiveness of
leflunomide. All three studies represent a valuable addition
to the literature on treatment of a condition that currently
has limited alternatives to long-term immunosuppression
with steroids, azathioprine, or cyclosporine.
Randomized trial of thymectomy in myasthenia
gravis
In this international multicentre randomised single-blind
trial of thymectomy in patients with non-thymomatous
MG, 126 participants were randomised to treatment with
extended trans-sternal thymectomy plus alternate-day
prednisone or treatment with alternate-day prednisone
alone. The dual primary outcome was the time-weighted
QMG score over 3 years and the time-weighted average
required dose of prednisone over 3 years. Secondary out-
comes addressed treatment safety and quality of life and
focused on 36 treatment-associated complications and 29
symptoms associated with glucocorticoids.
Sixty-six participants were randomised to the thymec-
tomy group of whom 58 underwent an extended trans-
sternal thymectomy within 30 days of randomisation. The
remaining eight participants declined surgery. Of the 60
participants randomised to the prednisone-only group,
eight had a thymectomy outside the trial protocol. The trial
was single-blinded as it was deemed unethical to perform a
sham thymectomy. All participants wore a black, high-
collared shirt to conceal any evidence of trans-sternal
incisions to maintain rater blinding. Patients were treated
with alternate-day prednisone starting at 10 mg, increasing
in 10 mg steps to a maximum 100 mg on alternate days for
participants not previously taking prednisone and 120 mg
for those already taking prednisone, with the goal of
achieving minimal-manifestation status. This was defined
as having ‘‘no symptoms or functional limitations from
myasthenia gravis, but there may be some weakness on
examination of some muscles’’. Once this was reached, the
prednisone was reduced by 10 mg every 2 weeks until
40 mg was reached, with subsequent tapering by 5 mg a
month to maintain the minimal-manifestation status.
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Pyridostigmine dose could not exceed 240 mg per day
during the tapering phase and plasmaphersis or intravenous
immunoglobulin was permitted in unstable patients.
In the thymectomy group, the time-weighted average
QMG scores were significantly lower with an estimated
difference in mean scores of 2.85 points. The average
alternate-day prednisone dose was 44 mg in the thymec-
tomy group compared to 60 mg in the prednisone-only
group; also statistically significant. Minimal-manifestation
status was reached in 67% of the thymectomy group
compared to 37% of the prednisone-only group. There was
no significant difference in treatment-associated compli-
cations between the groups.
Comment This study has demonstrated that routine
thymectomy in patients with MG has a positive effect on
QMG scores and reduces steroid dose required to maintain
minimal-manifestation state. In a study assessing the
validity of the QMG scale, patients with clinical
improvement in symptoms scored 2.3 points lower; there-
fore, a score of 2.85 is likely to be associated with mean-
ingful clinical improvement. This study provides class Ib
evidence for performing thymectomy in MG and may
result in this procedure being used with increasing fre-
quency as a treatment option.
Wolfe GI et al. (2016) N Engl J Med 375(6):511–21
A randomized controlled trial of methotrexate
for patients with generalized myasthenia gravis
Methotrexate is a selective inhibitor of dihydrofolate and is
commonly used as a steroid-sparing agent in a number of
autoimmune diseases. This study is a multicentre ran-
domised double-blind placebo-controlled trial designed to
determine whether methotrexate has similar benefits in
MG. Fifty participants were randomised to treatment with
methotrexate and prednisone or treatment with matching
placebo tablets and prednisone over 12 months. The pri-
mary outcome was the 9-month prednisone area under the
dose-time curve (AUDTC), chosen as the authors felt that
this most closely represents the experience of clinicians
treating MG due to the need to vary prednisone dosing
based on symptoms. The secondary outcomes focused on
clinical status and included change in QMG score, MG
Activities of Daily Living scale (MG-ADL), and MG
Quality of Life scale (MG-QOL).
Twenty-five participants were randomised to each
group. The methotrexate and placebo were over-encapsu-
lated to ensure blinding of investigators, evaluators, and
participants to treatment allocation. Participants were
commenced on four tablets per week of either 2.5 mg of
methotrexate or matching placebo, increasing by 2 tablets
by every 2 weeks until a weekly dose of eight tablets was
reached. A standardised protocol was then used to taper
prednisone based on symptoms.
Forty-two participants completed the 12-month study.
Eight participants withdrew from the study. One participant
from the methotrexate group withdrew because of travel
difficulties and seven participants from the placebo group
as a result of adverse symptoms. All were included in the
final analysis. There was no difference between groups of
the primary or secondary outcomes. The study concluded
that there was no steroid-sparing benefit for methotrexate
in MG.
Comment The large confidence intervals reported and
small sample sizes suggest that this study was underpow-
ered. The sample sizes were calculated to detect the
equivalent of a 31.4% reduction in the mean AUDTC over
9 months of treatment, so the study may have missed a
moderate effect of methotrexate. There is a question about
the appropriateness of the study duration, since a previous
azathioprine study required more than 15 months before a
reduction in prednisolone dose was detected. A further trial
with a larger sample size and a longer duration of follow-
up may be required before conclusively excluding
methotrexate as a potential steroid-sparing immunosup-
pressant in MG.
Pasnoor M et al. (2016) Neurology 87(1):57–64
Leflunomide treatment in corticosteroid-
dependent myasthenia gravis: an open-label pilot
study
Leflunomide is an immunosuppressant that blocks pyrim-
idine nucleotide biosynthesis and has been used in the
treatment of rheumatoid arthritis. Its active metabolite,
teriflunomide has also been investigated as a potential
treatment for multiple sclerosis and found to be associated
with lower relapse rate and less disability accrual compared
to placebo. This third paper reports the findings of an open-
label pilot study of leflunomide treatment in MG. The
primary purpose of the study was to examine the efficacy
of leflunomide in MG using the QMG and MG-ADL
scores. The study was not designed to assess the steroid-
sparing effects of the drug, although a comparison was
made of prednisone doses at the beginning and end of the
study.
Fifteen participants were enrolled in the study. All had
undergone thymectomy and were dependent on steroid
treatment. They were assigned to one of two groups based
on the duration of previous steroid treatment. The first
group consisted of 11 participants treated for longer than
6 months, and the second group had 4 participants treated
for less than 6 months. Both groups were given prednisone
and leflunomide which were administered orally at 20 mg
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daily for 6 months. There was no protocol for prednisone
dosing which was done at the discretion of the treating
clinician.
Following 6 months of treatment, there was a significant
improvement in QMG score by 3 points or more in 11
participants and an improvement in ADL score in 10 par-
ticipants. Twelve participants had their prednisone dose
reduced with a reduction in average dose from 24.3 to
12.3 mg per day which statistically significant. No major
adverse reactions were reported. Three participants repor-
ted minor side effects, including diarrhoea, transient
thrombocytopenia, gastric disturbance, hair thinning, and
rash.
Comment This is a small but promising pilot study
demonstrating that leflunomide may be an efficacious and
safe steroid-sparing immunosuppressant for MG. As was
the case in the second study, a longer duration of follow-up
would have been desirable given the previous 15-month
treatment duration required to establish the benefits of
azathioprine. A larger, placebo-controlled study over a
longer time period is planned by the authors to confirm the
findings of their pilot study and to further assess the safety
profile of leflunomide when used in patients with MG.
Chen P et al. (2016) J Neurol 263(1):83–8
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